Table 2. Incidence of aGvHD in period... | American Society of Hematology

Table 2.

Incidence of aGvHD in period 1993-1996

Risk factor	aGvHD, row %
Risk factor	0	I	II	III	IV
All patients	33	27	25	9	6
Sex
Male	33	28	24	9	6
Female	34	25	25	9	7
Age, y^*,^†
Younger than 20	42	26	13	11	8
20-40	35	26	25	9	5
Older than 40	29	27	26	10	8
Donor-recipient sex combination
Donor (F) + recipient (M)	32	28	24	10	6
Other	33	27	25	9	6
Interval between diagnosis and transplantation^*,^†
Shorter than 12 mo	37	26	22	9	6
12 mo or longer	27	28	29	9	7
aGvHD prevention^*
T-cell depletion	32	28	24	11	5
Cyclo alone	21	41	19	11	8
Cyclo + mtx	33	28	23	10	6
Other	62	13	13	5	7
Source of stem cells
BM	33	27	25	9	6
PB	30	28	23	11	8

Risk factor	aGvHD, row %
Risk factor	0	I	II	III	IV
All patients	33	27	25	9	6
Sex
Male	33	28	24	9	6
Female	34	25	25	9	7
Age, y^*,^†
Younger than 20	42	26	13	11	8
20-40	35	26	25	9	5
Older than 40	29	27	26	10	8
Donor-recipient sex combination
Donor (F) + recipient (M)	32	28	24	10	6
Other	33	27	25	9	6
Interval between diagnosis and transplantation^*,^†
Shorter than 12 mo	37	26	22	9	6
12 mo or longer	27	28	29	9	7
aGvHD prevention^*
T-cell depletion	32	28	24	11	5
Cyclo alone	21	41	19	11	8
Cyclo + mtx	33	28	23	10	6
Other	62	13	13	5	7
Source of stem cells
BM	33	27	25	9	6
PB	30	28	23	11	8

Abbreviations are explained in Table 1.

Indicates that the χ² test for the comparison of the incidence of aGvHD (yes vs no) has a P < .05.

Indicates that the χ² test for a linear trend over the grades 0 to IV (severity) comparing the risk factor levels is significant at the .05 level.